Mechanism: three receptors vs one
Semaglutide is a pure GLP-1 receptor agonist: slows gastric emptying, signals satiety to the hypothalamus, improves first-phase insulin response, lowers fasting glucose. That's the one lever. Retatrutide adds two more: GIP receptor agonism (potentiates GLP-1 satiety + direct adipose-tissue effects) and glucagon receptor agonism (stimulates hepatic lipolysis, drives liver-fat clearance, and can raise energy expenditure, shown in animal models and short human glucagon studies but not yet published for retatrutide itself). Each added receptor expands the weight-loss mechanism set: and the trial data shows it.
- Semaglutide: Single agonist (GLP-1)
- Retatrutide: Triple agonist (GLP-1 + GIP + glucagon)
- Why three matters: Glucagon agonism can raise energy expenditure (animal models and short human glucagon studies). Semaglutide has no glucagon arm.
Efficacy: trial readouts side by side
STEP-1 (semaglutide, NEJM 2021, 1,961 adults): 14.9% mean body-weight loss at 2.4 mg/wk through 68 weeks. Retatrutide's Phase 2 trial (NEJM 2023, 338 adults): 8.7%, 17.1%, 22.8%, and 24.2% at 1, 4, 8, and 12 mg/wk through just 48 weeks. The retatrutide curve was still descending at week 48. Phase 3 TRIUMPH-1 ran to 80 weeks and reported 28.3% average weight loss on 12 mg (May 2026). No head-to-head results are out yet. The first trial to run retatrutide against semaglutide, TRANSCEND-T2D-2 in type 2 diabetes, has finished enrolling and lists a primary completion date of August 2026, so for now the comparison is cross-trial: 24.2% at 48 weeks against 14.9% at 68 weeks, on different estimands.
- Semaglutide @ 2.4 mg (68 wk): 14.9% body-weight loss (STEP-1)
- Retatrutide @ 12 mg (48 wk): 24.2% body-weight loss (Phase 2)
- Cross-trial, not head-to-head: 24.2% at 48 weeks in the retatrutide Phase 2 against 14.9% at 68 weeks in STEP-1, measured on different estimands
Dosing: escalation protocols
Both require slow titration to manage GI side effects. Semaglutide for obesity (Wegovy): start 0.25 mg/wk, escalate 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg every 4 weeks. T2D dosing (Ozempic) caps at 1.0 mg/wk: that's why the weight-loss numbers people quote come from the obesity indication, not the diabetes indication. Retatrutide Phase 2 protocol: 2 → 4 → 8 → 12 mg every 4 weeks. Research-use community typically starts more conservatively (1-2 mg) to assess tolerance before scaling. Both are once-weekly subQ.
- Semaglutide titration (Wegovy): 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/wk, +1 step every 4 weeks
- Retatrutide titration: 2 → 4 → 8 → 12 mg/wk, +1 step every 4 weeks (Phase 2)
- Ozempic vs Wegovy disambiguation: Both semaglutide. Ozempic caps at 1.0 mg (T2D); Wegovy goes to 2.4 mg (obesity). The 14.9% weight-loss figure is at 2.4 mg, not 1.0 mg.
Safety: overlapping front-end, diverging tail
Shared GI profile: nausea (40-50%), vomiting (15-25%), diarrhea or constipation (~25%). Semaglutide carries the thyroid C-cell tumor boxed warning (rodent finding, no confirmed human signal); retatrutide is investigational and has no FDA label. Semaglutide has the longer post-market record of the two: FDA-approved in December 2017 for T2D and June 2021 for obesity, so more than eight years of population-level data. Both raise heart rate: Wegovy's label reports average rises of 1 to 4 beats per minute, and in retatrutide's Phase 2 the rise grew with dose, peaked at 24 weeks and declined after that, similar in size to GLP-1 receptor agonists per the trial authors. The trial reported no hepatotoxicity signal through 48 weeks, and a periodic CMP at top doses is still sensible.
- Shared GI side effects: Nausea ~45%, vomiting ~20%, GI motility changes ~25% (peak during titration, fade by week 4 of each dose)
- Semaglutide-specific advantage: More than eight years of post-market data since the December 2017 approval, no novel signals beyond the class
- Retatrutide in Phase 2: Heart rate rose with dose in Phase 2, peaked at 24 weeks and declined after that (similar in size to GLP-1 drugs, per the trial authors); no hepatotoxicity signal through 48 weeks
Cost: pharmacy + compounded + research-use channels
US retail semaglutide: Ozempic ~$900/month, Wegovy ~$1,300/month. Insurance coverage is broad for diabetes (Ozempic) but mixed for obesity (Wegovy). Compounded semaglutide lost its shortage cover in 2025: the FDA declared the shortage resolved in February 2025 and the grace periods for compounded copies ran out in April and May 2025. Compounding now needs a prescriber-documented clinical difference for an individual patient. Retatrutide is not FDA-approved, so there is no pharmacy or insurance pathway; it's strictly research-use. Research-use retatrutide tracked on BHG runs ~$0.16-0.42/mg, putting a 12 mg/wk protocol at roughly $8-20/week in raw molecule cost. Per kg lost over a 48-week protocol, retatrutide is dramatically cheaper today; that gap may compress when retatrutide hits pharmacy channels in 2027+.
- Semaglutide retail: $900-1,300/month US pharmacy (Ozempic vs Wegovy)
- Retatrutide research-use: $0.16-0.42/mg → ~$8-20/week at 12 mg dose
- Vendor prices: Both track on /compound/retatrutide and /compound/semaglutide
Who chooses which
Choose semaglutide if you want the longer safety record of the two, prescription access (Wegovy at 2.4 mg or Ozempic at 1.0 mg), insurance coverage when available, and a more predictable side-effect profile. Choose retatrutide if you prioritize maximum weight loss, you're willing to take the research-use pathway (no prescription, vendor due diligence required, COA verification + bloodwork monitoring on you), and you can wait out the Phase 3 + FDA approval timeline if you want the molecule to be legal. For BMI 35+ or aggressive recomp protocols, the absolute weight-loss difference matters; retatrutide wins on output. For mild-to-moderate obesity or T2D as primary indication, semaglutide's track record + price point still hold.
- Choose semaglutide if: Want the longer safety record, prescription/insurance pathway, T2D primary indication, or moderate weight-loss goal
- Choose retatrutide if: Goal is max weight loss, BMI 35+, willing to go the research-use route + monitor own labs